Steven Lichtman
Stock Analyst at Oppenheimer
(4.27)
# 455
Out of 4,712 analysts
67
Total ratings
48.94%
Success rate
19.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Lichtman
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
DXCM DexCom | Maintains: Outperform | $115 → $105 | $78.00 | +34.62% | 8 | Oct 25, 2024 | |
ZBH Zimmer Biomet Holdings | Maintains: Outperform | $145 → $135 | $105.40 | +28.08% | 7 | Oct 15, 2024 | |
MNKD MannKind | Maintains: Outperform | $10 → $12 | $6.52 | +84.05% | 2 | Aug 28, 2024 | |
ALC Alcon | Maintains: Outperform | $103 → $110 | $84.75 | +29.79% | 3 | Aug 22, 2024 | |
MDT Medtronic | Maintains: Perform | $92 → $94 | $79.61 | +18.08% | 10 | Aug 21, 2024 | |
RXST RxSight | Maintains: Outperform | $72 → $65 | $33.81 | +92.25% | 8 | Aug 6, 2024 | |
TNDM Tandem Diabetes Care | Maintains: Outperform | $47 → $58 | $36.87 | +57.31% | 1 | Jun 10, 2024 | |
BWAY BrainsWay | Maintains: Outperform | $10 → $11 | $9.22 | +19.31% | 5 | May 9, 2024 | |
ANGO AngioDynamics | Upgrades: Outperform | $12 | $9.05 | +32.60% | 2 | Apr 5, 2024 | |
MMSI Merit Medical Systems | Maintains: Outperform | $82 → $87 | $96.50 | -9.84% | 1 | Feb 29, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $58 → $68 | $89.68 | -24.17% | 2 | Feb 1, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $3.5 | $1.39 | +151.80% | 2 | Sep 19, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $300 → $275 | $263.36 | +4.42% | 5 | Jan 31, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $273 → $288 | $362.26 | -20.50% | 2 | Jul 28, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $105 | $149.51 | -29.77% | 3 | Jul 14, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | $150 | $24.08 | +522.92% | 1 | Jul 9, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $83 → $85 | $91.43 | -7.03% | 3 | Sep 4, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.82 | - | 2 | Apr 12, 2017 |
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $78.00
Upside: +34.62%
Zimmer Biomet Holdings
Oct 15, 2024
Maintains: Outperform
Price Target: $145 → $135
Current: $105.40
Upside: +28.08%
MannKind
Aug 28, 2024
Maintains: Outperform
Price Target: $10 → $12
Current: $6.52
Upside: +84.05%
Alcon
Aug 22, 2024
Maintains: Outperform
Price Target: $103 → $110
Current: $84.75
Upside: +29.79%
Medtronic
Aug 21, 2024
Maintains: Perform
Price Target: $92 → $94
Current: $79.61
Upside: +18.08%
RxSight
Aug 6, 2024
Maintains: Outperform
Price Target: $72 → $65
Current: $33.81
Upside: +92.25%
Tandem Diabetes Care
Jun 10, 2024
Maintains: Outperform
Price Target: $47 → $58
Current: $36.87
Upside: +57.31%
BrainsWay
May 9, 2024
Maintains: Outperform
Price Target: $10 → $11
Current: $9.22
Upside: +19.31%
AngioDynamics
Apr 5, 2024
Upgrades: Outperform
Price Target: $12
Current: $9.05
Upside: +32.60%
Merit Medical Systems
Feb 29, 2024
Maintains: Outperform
Price Target: $82 → $87
Current: $96.50
Upside: -9.84%
Feb 1, 2024
Maintains: Perform
Price Target: $58 → $68
Current: $89.68
Upside: -24.17%
Sep 19, 2023
Reiterates: Outperform
Price Target: $3.5
Current: $1.39
Upside: +151.80%
Jan 31, 2022
Upgrades: Outperform
Price Target: $300 → $275
Current: $263.36
Upside: +4.42%
Jul 28, 2021
Maintains: Perform
Price Target: $273 → $288
Current: $362.26
Upside: -20.50%
Jul 14, 2021
Downgrades: Perform
Price Target: $105
Current: $149.51
Upside: -29.77%
Jul 9, 2021
Initiates: Perform
Price Target: $150
Current: $24.08
Upside: +522.92%
Sep 4, 2020
Maintains: Perform
Price Target: $83 → $85
Current: $91.43
Upside: -7.03%
Apr 12, 2017
Downgrades: Perform
Price Target: n/a
Current: $0.82
Upside: -